Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20847617 | 0.92 | HDAC6 (0.40) | HDAC6HDAC8HDAC11HDAC3SLC6A2 | |
| SCHEMBL20847564 | 0.79 | HDAC6 (0.62) | HDAC6HDAC8HDAC11HDAC3 | |
| SCHEMBL20847648 | 0.77 | HDAC6 (0.46) | HDAC6HDAC8HDAC11HDAC3SLC6A2 | |
| SCHEMBL23783555 | 0.76 | KEAP1 (0.48) | HDAC6HDAC8HDAC11GPBAR1MAPT | |
| SCHEMBL20847646 | 0.74 | GAA (0.36) | SLC6A2SLC6A4GAAMAPT | |
| SCHEMBL20847759 | 0.74 | HDAC6 (0.52) | HDAC6HDAC8HDAC11HDAC3SLC6A2 | |
| SCHEMBL20839235 | 0.73 | HDAC6 (0.67) | HDAC6HDAC8HDAC11HDAC3 | |
| SCHEMBL20847595 | 0.72 | HDAC6 (0.48) | HDAC6HDAC8HDAC11HDAC3MAPT | |
| SCHEMBL20847470 | 0.72 | HDAC6 (0.50) | HDAC6HDAC8HDAC11HDAC3SLC6A2 | |
| SCHEMBL23792675 | 0.72 | GPBAR1 (0.46) | HDAC6GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277268-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2020-09-03 | — | — | US | disclosed |
| WO-2019056120-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277268-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKI67, PKD1, ETV6 | HDAC6 499/4885HDAC8 1916/4885HDAC11 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.